Supersaturated Oxygen (SSO2) Therapy in STEMI Treatments
Published: 06 December 2021
-
Views:
9324
-
Likes:
7
-
Views:
9324
-
Likes:
7
-
Up Next -
10m 41sPart 2 | Session 2 Evolution of STEMI Treatment -
2m 44sPart 2 | Session 3 SSO2 Mechanism of Action -
6m 46sPart 2 | Session 4 Clinical Results of SSO2 Therapy with Case Presentation -
9m 1sPart 2 | Session 5 Case Presentation by Dr A Schäfer -
24m 36sPart 2 | Session 6 Questions and Answers
-
2m 49sPart 3 | Session 1 Introduction -
13m 25sPart 3 | Session 2 Overview of the Problem: Microvascular Obstruction and Infarct Size in STEMI -
29mPart 3 | Session 3 Questions and Answers
-
3m 38sPart 4 | Session 1 Introduction -
11m 1sPart 4 | Session 2 Heart Failure Epidemic in STEMI -
45m 2sPart 4 | Session 3 Fireside Chat
-
4m 32sPart 1 | Session 1 Why is Infarct Size Reduction Important Gregg Stone, Robert Kloner
-
7m 22sPart 1 | Session 2 Impact of Microvascular Obstruction Robert Kloner, Gregg Stone
-
5m 51sPart 1 | Session 3 What is SSO2 Therapy Gregg Stone, Robert Kloner
-
11m 26sPart 1 | Session 4 Infarct Size and Clinical Outcomes Robert Kloner, Gregg Stone
-
7m 22sPart 1 | Session 5 SSO2 Therapy and Infarct Size Reduction Gregg Stone, Robert Kloner
-
20m 59sPart 1 | Session 6 Questions and Answers Gregg Stone, Robert Kloner
Overview
Despite advances in reperfusion with primary stenting, progress in STEMI outcomes has stalled over the past 20 years. With 90% of coronary blood flow in the capillaries, the answer might be in the microvasculature. TherOx SSO2 Therapy is the first FDA approved therapy shown to significantly reduce the infarct size in STEMI patients.
During this series of webinars on Supersaturated Oxygen (SSO2) Therapy, our faculty of renowned international experts will discuss and dissect the mechanisms and data around this promising new therapy for STEMI patients.
Key Objectives
- Understand how SSO2 Therapy works
- Hear about trends in STEMI treatment
- Explore the role of microvascular obstruction and infarct size in outcomes
- Understand the science behind SSO2 Therapy
Target Audience
This series is designed for the entire cardiology community:
- Interventional Cardiologists
- Cardiologists
- Clinical Fellows and Trainees
More from this programme
Part 1
Supersaturated Oxygen Therapy (SSO2): The Next Frontier in STEMI Treatment
Part 2
SSO2 Therapy in STEMI to Reduce Infarct Size: A Conversation with Global Thought Leaders
Part 3
Infarct Size, Microvascular Obstruction and Outcomes in STEMI: An Expert Panel Discussion
Part 4
Transforming STEMI Care: Bridging Interventional and Heart Failure Cardiology to Improve Patient Outcomes
This engaging session features the collaborative efforts of interventional and heart failure cardiologists in revolutionizing the management of ST-Elevation Myocardial Infarction (STEMI) and its impact on heart failure. Through a dynamic fireside chat format, our esteemed panelists will explore groundbreaking approaches and advancements that are reshaping STEMI care.
Faculty Biographies
Dan Burkhoff
Director
Dr Dan Burkhoff is currently the Director of Heart Failure, Hemodynamics and MCS Research at Cardiovascular Research Foundation, New York, US. Dr Burkhoff's interest include cardiovascular modeling and ventricular mechanics, cardiovascular monitoring, heart failure, device and pharmacologic treatments for heart failure, including left ventricular assist devices. He is also author of Harvi, an interactive simulation-based application for teaching and researching on ventricular mechanics and hemodynamics.
Steven Yakubov
Director
Dr Yakubov is the John H. McConnell Chair of Advanced Structural Heart Disease, System Medial Chief, Advanced Structural Heart Disease of OhioHealth and Medical Director of Cardiovascular Studies for the OhioHealth Research Institute at Riverside Methodist Hospital, Columbus, Ohio. He has been involved in numerous clinical trials to advance treatment options for cardiovascular disease and structural heart disease. He is a speaker at several annual major cardiovascular conferences and has numerous publications in major medical journals and book chapters. He has been instrumental in the development of new technology for the treatment of structural heart disease.
Andreas Schäfer
Deputy Director
Dr Andreas Schäfer currently holds the position of deputy director at Hannover Medical School and specialises in interventional cardiology. Dr Schäfer has been involved in multiple clinical trials and has published extensively in the field of interventional cardiology. In addition, he regularly speaks at conferences and educational events globally.
Richard Schatz
Dr Richard Schatz is research director of cardiovascular interventions at the Scripps Heart, Lung, and Vascular Center and director of gene and stem cell therapy. A recognized international expert in interventional cardiology, he has published and lectured extensively. His seminal work in coronary stents spurred a revolution in the treatment of coronary artery disease – more than 2 million of them are placed annually worldwide, with an immeasurable impact on relieving mortality and morbidity, improving patients’ lives, and reducing healthcare costs.